Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
IRAK3 DiscoveRx kinase panel
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of IRAK3 expressed in human PBMCs measured at 10 uM by KiNativ profiling analysis relative to control
Assay data:2 Tested
SummaryPubMed CitationRelated BioAssays by Target
KinomeScan assay: inhibition of IRAK3
Assay data:1 Active, 108 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
IRAK3(IRK3PFE1) Takeda global kinase panel
Assay data:1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, activity ≤ 1 µMRelated BioAssays by Target
IRAK3 Invitrogen Lab (UK) kinase screen (BI)
Assay data:1 Active, 1 Tested
NanoBRET (SGC-FFM) (IRAK3)
Dose response measurement (IRAK3)
Inhibition of human IRAK3 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control
Inhibition of DNA-tagged human IRAK3 assessed as percent of control at 50000 nM by qPCR analysis relative to control
Inhibition of human IRAK3 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control
Inhibition of human partial length IRAK3 (V147 to E596 residues) expressed in bacterial expression system assessed as residual activity at 10 uM by kinome scan method relative to control
Protac activity at CRBN/IRAK3 in human PBMC derived primary macrophages assessed as induction of IRAK3 degradation at 0.3 uM preincubated for 8 hrs followed by LPS-stimulation and measured after 8 to 32 hrs by Western blot analysis
Assay data:1 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Protac activity at CRBN/IRAK3 in human PBMC derived primary macrophages assessed as induction of IRAK3 degradation at 0.3 uM measured after 8 to 32 hrs by Western blot analysis
Protac activity at CRBN/IRAK3 in human THP1 cells assessed as induction of IRAK3 degradation at 0.1 to 10 uM measured after 24 hrs by Western blot analysis
Protac activity at CRBN/IRAK3 in human THP1 cells assessed as induction of IRAK3 degradation at 0.1 uM measured after 6 hrs in presence of 10 uM thalidomide by Western blot analysis
Protac activity at CRBN/IRAK3 in human THP1 cells assessed as induction of IRAK3 degradation at 0.1 uM measured after 6 hrs in presence of IRAK3 ligand cis-1-(4-(4-((5-Isopropylpyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-cyclohexyl)piperazin-1-yl)ethanone by Western blot analysis
Protac activity at CRBN/IRAK3 in human THP1 cells assessed as induction of IRAK3 degradation at 0.1 uM measured after 6 hrs in presence of NEDD8-activating enzyme inhibitor MLN4924 by Western blot analysis
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on